Fan Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Fan Zhao has a total of 187 co-authors. Here are the top co-authors by number of shared publications:
Alex Histed
19 shared publicationsAlyssa Nelson
19 shared publicationsAnish Suri
19 shared publicationsDharma R. Thapa
19 shared publicationsDominic R. Beal
19 shared publicationsEmily Spaulding
19 shared publications
Latest Publications
- 1 March 2024
- Published by Elsevier in Ceramics International
- Vol. 50 (11) , 18907-18914
Densification and microstructure evolution of NaNbO3 ceramic via ultrafast high-temperature sintering
- 1 March 2024
- Published by Elsevier in Ceramics International
- Vol. 50 (11) , 18907-18914
Densification and microstructure evolution of NaNbO3 ceramic via ultrafast high-temperature sintering
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven Malignancies
Supplementary Figure 1. Characterization of CUE-101 binding properties.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven Malignancies
Supplementary Figure 1. Characterization of CUE-101 binding properties.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 5 from CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven Malignancies
Supplementary Figure 5. Antitumor activity of mCUE-101 in TC-1 tumors.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 5 from CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven Malignancies
Supplementary Figure 5. Antitumor activity of mCUE-101 in TC-1 tumors.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Materials and Methods from CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven Malignancies
Supplementary Materials and Methods
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials and Methods from CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven Malignancies
Supplementary Materials and Methods
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven Malignancies
Supplementary Figure 2. Flow cytometric characterization of PBMC expansion cultures.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven Malignancies
Supplementary Figure 2. Flow cytometric characterization of PBMC expansion cultures.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 6 from CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven Malignancies
Supplementary Figure 6. Characterization of E7-specific CD8+ T cells in mice bearing TC-1 tumors.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 6 from CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven Malignancies
Supplementary Figure 6. Characterization of E7-specific CD8+ T cells in mice bearing TC-1 tumors.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven Malignancies
Supplementary Figure 3. Representative gating strategy for the analysis of blood and spleen samples from HLA-A2 transgenic mice.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven Malignancies
Supplementary Figure 3. Representative gating strategy for the analysis of blood and spleen samples from HLA-A2 transgenic mice.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 4 from CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven Malignancies
Supplementary Figure 4. Antitumor activity of mCUE-101 in established TC-1 tumors.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 4 from CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven Malignancies
Supplementary Figure 4. Antitumor activity of mCUE-101 in established TC-1 tumors.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven Malignancies
Purpose:To assess the potential for CUE-101, a novel therapeutic fusion protein, to selectively activate and expand HPV16 E711-20-specific CD8+ T cells as an off-the shelf therapy for the treatment of HPV16-driven tumors, including head and neck squamous cell carcinoma (HNSCC), cervical, and anal cancers.Experimental Design:CUE-101 is an Fc fusion protein composed of a human leukocyte antigen (HLA) complex, an HPV16 E7 peptide epitope, reduced affinity human IL2 molecules, and an effector attenuated human IgG1 Fc domain. Human E7-specific T cells and human peripheral blood mononuclear cells (PBMC) were tested to demonstrate cellular activity and specificity of CUE-101, whereas in vivo activity of CUE-101 was assessed in HLA-A2 transgenic mice. Antitumor efficacy with a murine surrogate (mCUE-101) was tested in the TC-1 syngeneic tumor model.Results:CUE-101 demonstrates selective binding, activation, and expansion of HPV16 E711-20-specific CD8+ T cells from PBMCs relative to nontarget cells. Intravenous administration of CUE-101 induced selective expansion of HPV16 E711-20-specific CD8+ T cells in HLA-A2 (AAD) transgenic mice, and anticancer efficacy and immunologic memory was demonstrated in TC-1 tumor-bearing mice treated with mCUE-101. Combination therapy with anti-PD-1 checkpoint blockade further enhanced the observed efficacy.Conclusions:Consistent with its design, CUE-101 demonstrates selective expansion of an HPV16 E711-20-specific population of cytotoxic CD8+ T cells, a favorable safety profile, and in vitro and in vivo evidence supporting its potential for clinical efficacy in an ongoing phase I trial (NCT03978689).
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven Malignancies
Purpose:To assess the potential for CUE-101, a novel therapeutic fusion protein, to selectively activate and expand HPV16 E711-20-specific CD8+ T cells as an off-the shelf therapy for the treatment of HPV16-driven tumors, including head and neck squamous cell carcinoma (HNSCC), cervical, and anal cancers.Experimental Design:CUE-101 is an Fc fusion protein composed of a human leukocyte antigen (HLA) complex, an HPV16 E7 peptide epitope, reduced affinity human IL2 molecules, and an effector attenuated human IgG1 Fc domain. Human E7-specific T cells and human peripheral blood mononuclear cells (PBMC) were tested to demonstrate cellular activity and specificity of CUE-101, whereas in vivo activity of CUE-101 was assessed in HLA-A2 transgenic mice. Antitumor efficacy with a murine surrogate (mCUE-101) was tested in the TC-1 syngeneic tumor model.Results:CUE-101 demonstrates selective binding, activation, and expansion of HPV16 E711-20-specific CD8+ T cells from PBMCs relative to nontarget cells. Intravenous administration of CUE-101 induced selective expansion of HPV16 E711-20-specific CD8+ T cells in HLA-A2 (AAD) transgenic mice, and anticancer efficacy and immunologic memory was demonstrated in TC-1 tumor-bearing mice treated with mCUE-101. Combination therapy with anti-PD-1 checkpoint blockade further enhanced the observed efficacy.Conclusions:Consistent with its design, CUE-101 demonstrates selective expansion of an HPV16 E711-20-specific population of cytotoxic CD8+ T cells, a favorable safety profile, and in vitro and in vivo evidence supporting its potential for clinical efficacy in an ongoing phase I trial (NCT03978689).